Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report
- DOI
- 10.3389/fimmu.2025.1679950
- Published
- 2025-12-02
- Container
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2025.1679950,
title = {Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report},
author = {Liping Sun and Juan Lang and Xueya Wu and Dan Shi and Jiefeng Sang and Zhongkui Xiong},
year = {2025},
journal = {Frontiers in Immunology},
doi = {10.3389/fimmu.2025.1679950},
url = {https://doi.org/10.3389/fimmu.2025.1679950}
}RIS
TY - JOUR TI - Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report AU - Liping Sun AU - Juan Lang AU - Xueya Wu AU - Dan Shi AU - Jiefeng Sang AU - Zhongkui Xiong PY - 2025 JO - Frontiers in Immunology DO - 10.3389/fimmu.2025.1679950 UR - https://doi.org/10.3389/fimmu.2025.1679950 ER -
APA
Sun, L., Lang, J., Wu, X., Shi, D., Sang, J., & Xiong, Z. (2025). Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1679950
Source records
- crossref · retrieved 2026-09-26T18:00:16.805Z